{"id":1002984,"date":"2026-09-11T10:37:46","date_gmt":"2026-09-11T14:37:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/levi-korsinsky-reminds-unicycive-therapeutics-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-november-2-2026-uncy\/"},"modified":"2026-09-11T10:37:46","modified_gmt":"2026-09-11T14:37:46","slug":"levi-korsinsky-reminds-unicycive-therapeutics-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-november-2-2026-uncy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/levi-korsinsky-reminds-unicycive-therapeutics-investors-of-the-pending-class-action-lawsuit-with-a-lead-plaintiff-deadline-of-november-2-2026-uncy\/","title":{"rendered":"Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 – UNCY"},"content":{"rendered":"

<\/p>\n

Levi & Korsinsky Reminds Unicycive Therapeutics Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of November 2, 2026 – UNCY<\/p>\n

A securities class action alleges Unicycive Therapeutics resubmitted its oxylanthanum carbonate New Drug Application without ever inspecting its third-party manufacturer’s facility for cGMP compliance. Pension funds, asset managers, and other fiduciaries that held UNCY during the Class Period may wish to evaluate lead plaintiff options.<\/i><\/p>\n

NEW YORK–(BUSINESS WIRE<\/a>)–Levi & Korsinsky, LLP notifies institutional investors in Unicycive Therapeutics, Inc. (NASDAQ: UNCY) that a class action lawsuit has been filed on behalf of shareholders who purchased securities between December 29, 2025 and June 29, 2026. Request an institutional investor loss assessment<\/a>. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com<\/a> or (212) 363-7500.<\/p>\n

UNCY closed at $4.69 on June 30, 2026, down $3.01 per share, or 39.1%, on unusually heavy trading volume, after having closed at a Class Period high of $8.56 on May 14, 2026. A fund holding 250,000 shares through that session absorbed roughly $752,500 in single-session mark-to-market losses. To be considered for lead plaintiff, investors must file by November 2, 2026.<\/p>\n

Notice to Institutional Holders<\/strong><\/p>\n

The pleading asserts that Unicycive never inspected or audited its third-party manufacturing vendor’s facility for compliance with current good manufacturing practices before resubmitting the OLC application, and therefore allegedly lacked a reasonable basis for its statements about the vendor’s return to FDA compliance. On June 30, 2026, the Company announced that the FDA had issued a second Complete Response Letter resting on the same third-party manufacturing deficiencies identified in the prior letter, and that the agency had not yet conducted its inspection of that facility during the resubmission review.<\/p>\n

ERISA and Fiduciary Considerations<\/strong><\/p>\n

Fiduciaries administering plan assets are generally expected to identify and evaluate recoverable losses arising from alleged securities violations. As averred in the action, purchases made between December 29, 2025 and June 29, 2026 were made at prices the complaint charges were artificially inflated.<\/p>\n

Fiduciary Obligations and Recovery Options<\/strong><\/p>\n